varespladib methyl

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2011
02420092011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Certain members of the phospholipase A(2) superfamily of enzymes have established causal involvement in atherosclerosis, thus at… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory… (More)
Is this relevant?
2011
2011
Secretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of cardiovascular… (More)
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
AIMS To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2011
2011
The action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby promoting… (More)
  • table 1
Is this relevant?
2010
2010
OBJECTIVES The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary… (More)
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2010
Review
2010
IMPORTANCE OF THE FIELD The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving… (More)
Is this relevant?
Review
2010
Review
2010
PURPOSE OF REVIEW Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipase A2 are potential… (More)
Is this relevant?
2009
2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the… (More)
Is this relevant?